

**BBL/SECT/64/2024-25****Date: 13 February 2025**

To,  
The Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai- 400 051

**NSE Symbol: BANKA****Sub: Outcome of Board Meeting dated 13 February 2025 and Integrated Filings (Financial)****Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

This is to inform you that the Board of Directors at its Meeting held today, i.e., 13 February 2025, has inter alia, based on the recommendation of the Audit Committee, considered and approved the un-audited standalone and consolidated financial results of the Company along with the Auditors' Limited Review Reports thereon, for the quarter and nine months ended 31 December 2024.

The Board of Directors has also agreed to extend corporate guarantee facility to its subsidiary, Megaliter Varunaa Private Limited towards credit facility to be availed by the subsidiary. *(Detailed disclosure is being intimated separately in this regard).*

A copy of the aforementioned Financial Results along with the Auditors' Limited Review Reports thereon pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") is enclosed herewith.

We are also arranging to upload the aforesaid Financial Results on the Company's website at [www.bankabio.com](http://www.bankabio.com) and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

This intimation shall also be considered as Integrated Filing (Financial) for the quarter ended 31 December 2024 pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular

No. SEBI/HO/CFD/CFDPoD-2/CIR/P/2024/185 dated 31 December 2024, read with NSE Circular No. NSE/CML/2025/02 dated 2 January 2025.

The meeting commenced at 04:30 PM and concluded at 05:50 PM.

We request you to kindly take note of the same in your record.

Thank you,

**For Banka BioLoo Limited**

**Nitika Lakhotia**  
**Company Secretary & Compliance Officer**

*Encl: As above*



**Independent Auditor's Review Report on the Unaudited Standalone Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter and nine months ended December 31, 2024 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular, is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.




5. The financial results shown under columns "Quarter ended 31.12.2023 -Unaudited," "Nine months ended 31.12.2023 - Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion.

**For B.D. Saboo and Associates**

Chartered Accountants

Firm Registration No: 003505s



**Shyam Sundar Modani**

Partner

Membership No: 213530

Place: Hyderabad

Date: 13-02-2025

UDIN: 252135306MILLR8334

Banka BioLoo Limited

Unaudited STANDALONE statement of financial results for the quarter and nine months ended 31.12.2024

Rs In Lakhs

Sl. No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
1	<b>Income</b>						
	Revenue from Operations	1,418.8	1,434.0	1,474.9	4,091.6	3,341.1	4,997.5
	Other income	11.4	8.3	19.4	38.5	57.5	76.7
	<b>Total Income</b>	<b>1430.18</b>	<b>1442.32</b>	<b>1494.25</b>	<b>4130.09</b>	<b>3398.65</b>	<b>5074.11</b>
2	<b>Expenses</b>						
	Cost of materials consumed	461.50	355.24	347.30	1035.10	829.44	1175.13
	Changes in inventories of finished goods & work- in-progress	(2.55)	14.09	125.51	81.22	158.28	546.85
	Operating Expenses	145.28	131.37	83.69	330.46	207.34	329.84
	Employee benefits expense	757.96	691.53	670.95	2151.14	1729.92	2358.10
	Finance costs	71.98	61.84	51.78	201.68	143.74	200.58
	Depreciation and amortisation expense	46.22	44.83	42.84	136.16	126.96	172.36
	Other expenses	101.53	88.58	63.75	240.39	177.05	249.83
	<b>Total expenses</b>	<b>1581.93</b>	<b>1387.48</b>	<b>1385.81</b>	<b>4176.15</b>	<b>3372.73</b>	<b>5032.69</b>
3	<b>Profit before exceptional items and tax</b>	<b>(151.75)</b>	<b>54.84</b>	<b>108.44</b>	<b>(46.06)</b>	<b>25.92</b>	<b>41.42</b>
4	<b>Exceptional items</b>	-	712.27	-	712.27	-	-
5	<b>Profit/(loss) before tax.</b>	<b>(151.75)</b>	<b>(657.43)</b>	<b>108.44</b>	<b>(758.33)</b>	<b>25.92</b>	<b>41.42</b>
6	<b>Tax expense</b>						
	(1) Current tax	(13.46)	6.41	-	-	2.75	-
	(2) Taxes for earlier years	-	-	-	-	-	1.93
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	8.16	(11.25)	-	(1.59)	(7.19)	6.84
	<b>Total Tax expense</b>	<b>(5.30)</b>	<b>(4.84)</b>	<b>-</b>	<b>(1.59)</b>	<b>(4.44)</b>	<b>8.77</b>
7	<b>Profit after tax</b>	<b>(146.45)</b>	<b>(652.58)</b>	<b>108.44</b>	<b>(756.74)</b>	<b>30.36</b>	<b>32.65</b>
	<b>Other comprehensive income</b>						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	-	-	-	-	-	20.85
	Income tax effect on items that will not be reclassified	-	-	-	-	-	(5.25)
8	<b>Other comprehensive income for the year</b>	-	-	-	-	-	<b>15.60</b>
9	<b>Total comprehensive income for the year</b>	<b>(146.45)</b>	<b>(652.58)</b>	<b>108.44</b>	<b>(756.74)</b>	<b>30.36</b>	<b>48.25</b>
10	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66	1084.66	1084.66
11	Earnings per share						
	Basic Earnings per share (in Rs.)	(1.35)	(6.02)	1.00	(6.98)	0.28	0.30
	Diluted Earnings per share (in Rs.)	(1.35)	(6.02)	1.00	(6.98)	0.28	0.30
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

For & on behalf of board of directors

Place: Hyderabad

Date: 13.02.2025

Vishal Murarka

CEO & Executive Director

DIN: 06729485

**Notes:**

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 February 2025.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter & nine months ended 31 December 2024 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2024.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. Enzotech Solutions Private Limited, a wholly-owned subsidiary of the Company, has approved the filing of an application under Section 6 read with Section 10 of the Insolvency and Bankruptcy Code, 2016, to initiate a voluntary Corporate Insolvency Resolution Process (CIRP) before the Hon'ble National Company Law Tribunal (NCLT), Chennai Bench. Considering this development, while preparing the standalone financial statements in accordance with Ind As 36 management of Banka BioLoo Limited has evaluated the recoverability of assets (Investment & Loans to Subsidiary) and one-time provision classified as an exceptional item amounting to ₹712.27 lakhs has been recognized, aligning with the principles outlined in Ind AS 36. These provisions will be continuously reviewed and updated based on further developments in the CIRP proceedings and any subsequent financial implications.

8. Reclassification of Other Expenses

During the current financial year, the Company has regrouped certain expenses previously classified under "Other Expenses" into two categories:

- **Operating Expenses** – Includes costs directly associated with the core operations of the business.
- **Other Expenses**– Comprises expenses that do not directly relate to the operational activities.

9. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For **Banka Bioloo Limited**

**Vishal Murarka**

CEO & Executive Director

DIN: 06729485

Place: Hyderabad

Date: 13 February 2025



**Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Consolidated unaudited financial results of **BANKA BIOLOO LIMITED** ("the Parent") its Subsidiaries (the Parent and Subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associate for the quarter ended December 31, 2024 and for the period from April 1, 2024 to December 31, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities.

**Holding Company**

BANKA BIOLOO LIMITED

**Subsidiaries**

1. ENZOTECH SOLUTIONS PRIVATE LIMITED – Wholly Owned Subsidiary
2. MEGALITER VARUNAA PRIVATE LIMITED

**Associate**

SAI BANKA SPV PRIVATE LIMITED (with a share of 50% to the holding company)





Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements

**5. Other Matter**

We did not review the interim financial information of two subsidiaries included in the unaudited consolidated financial results, which have not been reviewed by their auditor, whose interim financial information reflects total revenues of Rs. 175.69 Lacs and Rs.288.12 Lacs, total net loss after tax of Rs.5.86 Lacs and Rs.650.64 Lacs and total comprehensive loss of Rs.5.86 Lacs and Rs.650.64 Lacs for the quarter ended December 31, 2024, and for the period from April 1, 2024, to December 31, 2024, respectively as the consolidated unaudited financial results. The statement also includes the financial results of one associate as mentioned above, whose share of net profit after tax of Rs. 0.92 Lacs and Rs.2.08 Lacs total comprehensive income of Rs. 0.92 Lacs and Rs.2.08 Lacs for the quarter ended December 31, 2024, and for the period from April 1, 2024, to December 31, 2024, respectively, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed by the auditors, and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group

6. The financial results shown under columns "Quarter ended 31.12.2023 -Unaudited," "Nine months ended 31.12.2023 -Unaudited" and "Year ended 31.03.2024 -Audited" contained in the statement have been reviewed/audited by PRSV and Co LLP, the predecessor auditor, on which they have issued an unmodified conclusion/opinion. Our conclusion on the Statement is not modified in respect of the above matter.

**For B.D. Saboo and Associates**

Chartered Accountants

Firm Registration No. 0035055

**Shyam Sundar Modani**

Partner

Membership No. 213530

Place: Hyderabad

Date: 13-02-2025

UDIN: 25213530BM11LS4928



Banka BioLoo Limited

Unaudited CONSOLIDATED statement of financial results for the quarter and nine months ended 31.12.2024

Rs. In Lakhs

S. No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
1	<b>Income</b>						
	Revenue from Operations	1404.13	1241.14	1395.68	3933.82	3368.31	4999.62
	Other income	11.36	8.30	11.01	30.99	37.46	49.45
	<b>Total Income</b>	<b>1415.49</b>	<b>1249.44</b>	<b>1406.69</b>	<b>3964.81</b>	<b>3405.76</b>	<b>5,049.06</b>
2	<b>Expenses</b>						
	Cost of materials consumed	394.92	348.28	228.94	980.88	733.51	1077.49
	Changes in inventories of finished goods & work-in-progress	(2.55)	100.39	122.41	167.52	169.73	546.42
	Operating Expenses	145.71	131.37	86.14	330.89	215.11	337.61
	Employee benefits expense	759.05	691.53	677.78	2152.23	1763.14	2393.12
	Finance costs	100.86	85.07	65.21	273.38	184.01	247.45
	Depreciation and amortisation expense	62.94	61.84	56.50	186.62	157.46	218.87
	Other expenses	104.27	417.64	102.49	572.84	231.20	282.33
	<b>Total expenses</b>	<b>1565.19</b>	<b>1836.12</b>	<b>1339.46</b>	<b>4664.36</b>	<b>3454.17</b>	<b>5,103.29</b>
3	Share of profit/(loss) of Associates	0.92	0.43	0.10	2.08	1.47	(2.10)
4	<b>Profit/(loss) before tax exceptional items</b>	<b>(148.78)</b>	<b>(586.25)</b>	<b>67.33</b>	<b>(697.47)</b>	<b>(46.94)</b>	<b>(56.33)</b>
5	<b>Exceptional items</b>	-	31.51	-	31.51	-	-
6	<b>Profit/(loss) before tax</b>	<b>(148.78)</b>	<b>(617.77)</b>	<b>67.33</b>	<b>(728.98)</b>	<b>(46.94)</b>	<b>(56.33)</b>
7	<b>Tax expense</b>						
	(1) Current tax	(13.46)	6.41	-	-	2.75	-
	(2) Taxes for earlier years	-	-	-	-	-	1.93
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	10.21	(11.20)	(1.71)	0.33	(7.26)	8.85
	<b>Total Tax expense</b>	<b>(3.24)</b>	<b>(4.78)</b>	<b>(1.71)</b>	<b>0.33</b>	<b>(4.51)</b>	<b>10.78</b>
8	<b>Profit after tax</b>	<b>(145.54)</b>	<b>(612.98)</b>	<b>69.03</b>	<b>(729.31)</b>	<b>(42.43)</b>	<b>(67.11)</b>
	<b>Other comprehensive income</b>						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations	-	-	-	-	-	20.85
	Income tax effect on items that will not be reclassified	-	-	-	-	-	(5.25)
9	<b>Other comprehensive income for the year</b>	-	-	-	-	-	<b>15.60</b>
10	<b>Total comprehensive income for the year</b>	<b>(145.54)</b>	<b>(612.98)</b>	<b>69.03</b>	<b>(729.31)</b>	<b>(42.43)</b>	<b>(51.50)</b>
	<b>Attributable to</b>						
	Shareholders of the Company	(145.50)	(612.83)	70.13	(729.02)	(41.47)	(49.64)
	Non controlling interest	(0.04)	(0.16)	(1.10)	(0.29)	(0.96)	(1.86)
11	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1084.66	1084.66	1084.66	1084.66	1084.66
12	<b>Earnings per share</b>						
	Basic Earnings per share (in Rs.)	(1.34)	(5.65)	0.65	(6.72)	(0.38)	(0.6)
	Diluted Earnings per share (in Rs.)	(1.34)	(5.65)	0.65	(6.72)	(0.38)	(0.6)
		<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Annualised)</i>

For & on behalf of board of directors

Place: Hyderabad  
Date: 13.02.2025

Vishal Murarka  
CEO & Executive Director  
DIN: 06729485

**Notes:**

1. The above statement of unaudited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 February 2025.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards (“INDAS”) prescribed under section 133 of the Companies Act 2013 (“the Act”) read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

<b>Name of the entity</b>	<b>Status</b>
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Consolidated Financial Results for the quarter & nine months ended 31 December 2024 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31 March 2024.
6. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. Enzotech Solutions Private Limited, a wholly-owned subsidiary of the Company, has approved the filing of an application under Section 6 read with Section 10 of the Insolvency and Bankruptcy Code, 2016, to initiate a voluntary Corporate Insolvency Resolution Process (CIRP) before the Hon’ble National Company Law Tribunal (NCLT), Chennai Bench. Considering this development, management has evaluated the recoverability of assets and the necessity for provisions in the consolidated financial statements in accordance with Ind AS 36. Consequently, an amount of Rs:-31.51 Lakhs provision been recognized towards impairment of goodwill, aligning with the principles outlined in Ind AS 36. These provisions will be continuously reviewed and updated based on further developments in the CIRP proceedings and any subsequent financial implications.

8. Reclassification of Other Expenses

During the current financial year, the Company has regrouped certain expenses previously classified under "Other Expenses" into two categories:

- **Operating Expenses** – Includes costs directly associated with the core operations of the business.
  - **Other Expenses**– Comprises expenses that do not directly relate to the operational activities.
9. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For **Banka Bioloo Limited**

**Vishal Murarka**  
CEO & Executive Director  
DIN: 06729485

Place: Hyderabad  
Date: 13 February 2025

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE QUALIFIED INSTITUTIONS PLACEMENT ETC.**

- Not Applicable for this quarter

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES.**

- Not Applicable for this quarter

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter)**

- Not Applicable for this quarter

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

- Not Applicable for this quarter